Pancreatic adenocarcinoma (PDAC) lacks efficient biomarkers. Mucins are glycoproteins that can carry aberrant glycosylation in cancer. Our objective was to identify cancer-related glycan epitopes on MUC1 and MUC5AC mucins in PDAC as potential biomarkers. We have analysed the tumourassociated carbohydrate antigens sialyl-Lewis x (SLe x ) and sialyl-Tn (STn) on MUC1 and MUC5AC in PDAC tissues. The selected cohort for this study consisted of twenty-one PDAC tissues positive for SLe x antigen and three normal pancreas specimens as controls. STn expression was shown in 76% of the PDAC tissues. MUC1 and MUC5AC were detected in 90% of PDAC tissues. We performed in situ proximity ligation assay combining antibodies against mucins and glycan epitopes to identify specific mucin glycoforms. MUC1-SLe x and MUC5AC-SLe x were found in 68% and 84% respectively, of the mucin expressing PDAC tissues, while STn hardly colocalized with any of the evaluated mucins. Further analysis by Western blot of MUC5AC and SLe x in eight PDAC tissue lysates showed that six out of eight cases were positive for both markers. Moreover, immunoprecipitation of MUC5AC from positive PDAC tissues and subsequent SLe x immunodetection confirmed the presence of SLe x on MUC5AC. Altogether, MUC5AC-SLe x glycoform is present in PDAC and can be regarded as potential biomarker.
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Introduction
Pancreatic adenocarcinoma (PDAC) is estimated to be the third leading cause of cancer death in the United States [1] and is projected to become the second cause of cancer-related death by 2030 [2] .
PDAC is one of the cancers with the lowest survival rate (7% in 5 years), due to a late diagnosis and the intrinsic aggressiveness of this tumour [3] . Unfortunately, and in contrast to the declining trends for most cancers, PDAC is one of the few neoplasms with increasing incidence and mortality in both genders [1, 4] .
Despite the efforts made in the last decades to discover new biomarkers, there is still a lack of biomarkers with enough specificity and sensitivity. This reduces the chances of detection of PDAC in early stages, when curative procedures are most effective [5] . For the majority of patients the only available treatment is the administration of gemcitabine, a chemotherapeutic agent that has shown beneficial effects in only 20-30% of patients [6, 7] .
Mucins are high molecular weight glycoproteins expressed on epithelial cells. A multitude of oligosaccharides are attached to the polypeptide backbone of mucins which can be bound to the cell membrane or secreted into the organ lumen. Mucins constitute a selective barrier and play an important role in cell adhesion, immune response, cell signalling and in the renewal and differentiation of the epithelium [8] [9] [10] . Mucin expression and their glycosylation are altered in many tumours [11, 12] , including breast [13] , colon [14, 15] , gastric [16] [17] [18] , lung [19] , and PDAC [20, 21] . These alterations influence cellular growth, differentiation, malignant transformation, adhesion, invasion and immune surveillance [8, 11, 22, 23] .
MUC1 is a membrane-bound mucin that contains a variable number of tandem repeats (VNTR), between 20 and 125, which are abundantly O-glycosylated. Its molecular mass is therefore variable ranging from 120-225 kDa (protein backbone) and significantly larger when glycosylated, up to 500 kDa. MUC1 can also be secreted after cleavage of its extracellular domain. It is expressed at the apical surface of ductal epithelia of tissues, including breast, pancreas, bronchus and the gastrointestinal tract [17, 24, 25] . In normal pancreas, the common staining of MUC1 is at the cytoplasmic level in acinar cells and in the apical area of ductal cells [26] , and it is well-established that MUC1 is overexpressed in malignant situation [26, 27] . MUC5AC is a secreted mucin of a polypeptide chain of approximately 119  120  121  122  123  124  125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177 586 kDa, but with a much higher molecular weight especially due to the large number of Oglycosylated chains attached to Ser and Thr residues in the VNTR regions. It is only expressed in 2-4% of healthy pancreas [6] . Regarding PDAC, MUC5AC has been shown to be expressed in the cytoplasm and is de novo expressed in around 75-92% of the PDAC cases [27] [28] [29] and is also detected in 70% of PanIN1A cases, which is the earliest stage of the most common precursor lesions of PDAC [27] .
Aberrant glycosylation of cell surface glycolipids, membrane associated glycoproteins and secreted glycoproteins is a universal feature of malignant transformation [23, [30] [31] [32] . For instance, in malignant pancreatic tissues the carbohydrate antigens sialyl-Lewis x (SLe x ) and sialyl Tn (STn) have been described to be commonly expressed over 80% [33, 34] and 77% [27] respectively, while they are not detected in healthy pancreatic specimens [33, 35] . Moreover, SLe x and STn expression have been associated with tumour progression and metastasis [36, 37] . STn is an O-linked disaccharide which consists of an α2,6-linked N-acetylneuraminic acid attached to N-acetylgalactosamine and is often aberrantly expressed in the neoplastic lesions including PDAC [32] . SLe x epitope is a terminal structure (N-acetylneuraminic acid α2,3-Galactoseβ1,4[Fucose α1,3]N-acetylglucosamine) that can be found in either N-or O-glycosylated molecules [32, 38] .
Mucins are known to be major carriers of tumour associated carbohydrate antigens and, since they are overexpressed in adenocarcinomas, these glycan alterations are highly amplified on the surface of tumour cells [12] . In gastric tissues, a recent study that characterizes mucin O-glycosylation, reports the presence of sialylated glycans, including sialyl-Lewis antigens. A higher level of sialylation and sulfation on gastric O-glycans were found in cancerous tissue compared to healthy tissue [18] . In colon cancer, an increase expression of a core 3 sialyl-Le x hexasaccharide, which appeared to compete with its sulfo-Le x counterpart in normal tissue, was described on MUC2, suggesting its use as a potential marker of malignant transformation [15] . Therefore, the detection of the cancer related glycosylation on mucins could give rise to more specific and /or sensitive cancer diagnostic markers.
The expression of STn antigen on MUC1 and MUC5AC has been previously described in stomach, colon, lung, breast and ovarian tumours [39] . Recently, Remmers and coauthors have shown the expression of Tn/STn on MUC1 in PDAC tissues (91%) using an antibody directed to Tn/STn MUC1   178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236 glycoforms [40, 41] . The SLe x epitope on MUC1 and MUC5AC has been identified in colon, gastric, ovarian and breast carcinomas [17, 39, [42] [43] [44] [45] , but to our knowledge it has not been investigated in PDAC tissues.
Here we have used the in situ proximity ligation assay (PLA) to evaluate the glycan epitopes SLe x and STn on MUC1 and MUC5AC mucins in a cohort of PDAC tissues. In situ PLA provides information of two epitopes in close proximity and therefore has been used to report the colocalization of two antigens indicating, in our case, the expression of a particular glycan epitope on a specific mucin. Our results showed that the expression of SLe x on MUC1 and MUC5AC was observed in 68% and 84% of the mucin expressing PDAC tissues, respectively. In a second approach, PDAC tissues were assayed for MUC5AC and SLe x by western blotting and 75% of them showed positivity for both markers. An immunoprecipitation protocol using specific antibodies against MUC5AC was set up. MUC5AC was immunocaptured in selected PDAC tissues that were individually positive for MUC5AC and SLe x .
These immunoprecipitated samples were then probed for SLe x , and showed that the SLe x epitope was present on MUC5AC.
Materials and methods

Human tissue samples
Pancreatic tissues were obtained from the Hospital Dr. Josep Trueta (Girona, Spain) from patients undergoing surgical resection following the standard operating procedures of its Ethics Committee.
Normal pancreatic tissue refers to adjacent, non-tumour pancreatic tissue from patients with pancreatic-related disorders. The histopathologic features of the resected specimens were confirmed by biopsy or image examination by the Digestive and Pathology Units and classified according to the 
Immunohistochemistry
Paraffin sections were dewaxed and rehydrated. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol for 10 min, and then sections were incubated with normal rabbit serum diluted 1/5 in PBS containing 10% BSA. Normal serum excess was removed and replaced by specific primary antibody in the appropriate concentration (Table 1) antibodies (Vectastain Elite ABC kit) in 1.5% of goat serum or 1.5% of horse serum, respectively in PBS, following the protocol described in [47] . CSLEX antibody (at 1/20 dilution) (BD Biosciences, San Jose, CA) was used to compare the SLe x immunostaining obtained with the KM93 antibody. 
In situ Proximity Ligation Assay
In situ Proximity Ligation Assay (PLA) was performed in paraffin sections from controls and PDAC cases for colocalization analysis of SLe x and STn antigens with the MUC1 and MUC5AC mucins. 355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412 The analyses of the colocalization of MUC1 and MUC5AC with SLe x epitope were performed using secondary antibodies with oligoprobes. The procedure was similar to as previously described for the PLA with incubations of VU4H5, CLH2 (both IgGs subtypes) and KM93 (IgM subtype) primary antibodies (same conditions as for the immunohistochemistry) followed by 1h incubation at 37 ºC with the goat anti-mouse IgG1 and goat anti-mouse IgM oligoprobe secondary antibodies, diluted 1/300.
Imaging analysis of the PLA signal was performed with the Duolink Image Tool software (SigmaAldrich). These quantifications were performed for the imaging analysis of the PLA results of SLe x -MUC1 and SLe x -MUC5AC colocalization for each of the tissues. Briefly, several representative images per case were subjected to the software analysis and the median of positive blobs (positive PLA events) was set up for each case. Then, the median of positivity for each PLA combination was determined and 3 categories were established as follows: +++ (positive cases whose median is higher than 75% of the overall median); ++ (positive cases higher than 25% and lower than 75%); and + (positive cases lower than 25%). 414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471 
Immunoprecipitation
For immunoprecipitation assays, cell lysates containing equal amounts of protein (500 µg) were reduced in buffer containing dithiothreitol such that the final concentration when mixed with sample was 10 mM. After 2 h incubation at 37 ºC, fresh iodoacetamide was added to a final concentration of 25 mM and samples were incubated at room temperature for 30 minutes in the dark.
After reduction and alkylation, samples were desalted and concentrated using Amicon Ultra-0.5 3kDa
Centrifugal Filter Devices (Millipore) which had been previously passivated with 5% Brij-35 (Sigma).
Next, samples were diluted in incubation buffer,50 mM Tris pH 7.4, 150 mM NaCl and 1% Triton X-100, 5mM EDTA and protease inhibitors (complete ultratablets from Roche), and precleared with 100 µL of Protein G agarose resin for two hours at 4 ºC. The precleared samples were incubated with 20 µL of anti-MUC5AC polyclonal antibody (Lum5.1) for two hours at 4 ºC. The immunocomplexes were then captured by incubating samples with Protein G agarose resin packed into a spin column (Corning Costar Spin-X, New York, NY) overnight at 4 ºC. Protein G column were centrifuged and washed three times with washing buffer (50 mM Tris pH 7.4, 150 mM NaCl and 1% Triton X-100).
MUC5AC bound to the Lum5.1 antibody was eluted after boiling the sample with Laemmli buffer containing 1.25% β-mercaptoethanol. 473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531 Twenty micrograms of each protein lysate or immunoprecipitated MUC5AC from tissues were prepared on Laemmli sample buffer containing 1.25% β-mercaptoethanol and heated at 95ºC for 5 min. Samples were then loaded in duplicate and separated with a 3% stacking 5% resolving gel and transferred to a PVDF membrane for 4 h at 100 V in Towbin buffer (25 
Western Blot
Results
Expression of sialylated glycan epitopes (SLe x and STn) in pancreatic tissues
First, we analysed the presence of the carbohydrate antigens SLe x and STn by immunohistochemistry.
Positive SLe x staining was the criteria to select the cohort of PDAC tissues of this work. From our   532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590 initial cohort of 25 PDAC tissues, 21 were SLe x positive corresponding to 84% of the total samples, which is in agreement with the literature [33, 34] . Since several studies have described SLe x expression using CSLEX antibody, we compared the immunostaining pattern of the antibody KM93 with that of CSLEX on four PDAC tissues and a control tissue. Both antibodies showed the same staining pattern in the luminal and cytoplasmatic areas of ductal cancer cells from the four PDAC tissues and no staining was detected in the control tissue (Fig.S1) . From the 21 SLe x positive tissues, 16 were also positive for STn and two were STn positive staining in few sparse cells (Tables 2 and 3 ).
The 21 selected tissues were analysed for mucin expression and PLA experiments. As expected, both tumour-associated carbohydrate antigens were not expressed in normal pancreas tissues (Fig.1). 
Expression of MUC1 and MUC5AC in pancreatic tissues
The immunohistochemical analysis with VU4H5 antibody showed MUC1 expression in normal and in most of the PDAC tissues (Tables 3 and 4) . To our knowledge, this is the first time that the VU4H5, which is specific against APDTRPAP in the hypoglycosylated VNTR region of MUC1, has been tested in pancreatic tissues. In normal pancreas, MUC1 was stained in the acinar cells and faintly in some duct cells ( Fig. 2A-C) , as previously described [20] . Most PDAC tissues (Fig. 2D-I ) were positively stained, however two cases stained only in few sparse cells. These two samples were then assessed using M8 antibody (anti-MUC1, Table 1 ), which targets the DTR within the VNTR extracellular domain [48] and it was observed higher positivity in tumour cells when compared withVU4H5 staining (data not shown). VU4H5 recognises the non-glycosylated APDTRPAP epitope whereas M8 antibody also recognises this epitope when it is glycosylated [49] and this can explain the increase in MUC1 positivity when using the M8 antibody. PDAC cells from well to poor differentiated tumours presented cytoplasmic staining with more intense membranous staining when compared to controls. MUC1 was also detected in secretions.
MUC5AC is a mucin which is neo-expressed in pancreas under malignant conditions. The expression of this mucin in the three controls were negative (Fig. 2J-L) while 90% of the PDAC samples were positively stained (Fig. 2M-R) . MUC5AC staining was localized in the mucus and in some cases within the secretory compartments of ductal cells of cancer tissues. This indicates that epithelial cells 591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649 of PDAC are producing and secreting MUC5AC. The CLH2 antibody recognizes a tandem repeat sequence of the MUC5AC independently of glycosylation.
Expression of sialylated antigens on MUC1 and MUC5AC in PDAC tissues.
In situ PLA is a technique based on the detection of two epitopes located in close proximity employing oligonucleotide-conjugated antibodies (PLA probes). When two antigens are in close proximity, a bridging sequence links the two oligonucleotide sequences present in the different antibodies and a template for a rolling circle amplification is formed. Fluorescently labelled oligonucleotides hybridise with the product of the amplification generating easily detected fluorescent signal [50] .
All tissues of the cohort including control and negative samples (with negative staining for at least one of the four antigens analysed) were PLA tested. All healthy tissues presented negative PLA results since it was not possible to detect SLe x or STn by IHC.
In situ PLA showed colocalization of SLe x with MUC1 in 68% of the PDAC tissues that were individually positive for both antigens (Table 5 , Fig. 3A-F) . Staining intensity results for each of the tissues examined by PLA and subjected to subsequent imaging analysis are shown in Table 6 . The colocalization was detected in the apical area of the well and moderately differentiated PDAC ducts and in the secreted mucus (Fig. 3C) . Moreover, MUC1 bearing SLe x could be detected in the tumour cells of poorly differentiate tissues (Fig. 3F) . Among the positive tissues for MUC1-SLe x colocalization, about one third of the tissues were faintly positive.
Regarding MUC5AC-SLe x PLA, 16 out of 19 PDAC tissues (84%) that expressed individually both MUC5AC and SLe x were MUC5AC-SLe x positive (Tables 5 and 6 , Fig. 4A-I ). Regarding the 3 negative tissues for MUC5AC-SLe x , 2 of them were faintly positive (<25%) and one moderately positive (25-60%) for MUC5AC by immunohistochemistry. The colocalization was also found in the apical area of the well and moderately differentiated PDAC ducts (Fig. 4C) , in the secreted mucus (Fig. 4F ) and in the tumour cells of poorly differentiated tumours (Fig. 4I) 650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694  695  696  697  698  699  700  701  702  703  704  705  706  707  708 some isolated fluorescent dots in the mucus for MUC5AC-STn (Table 5 , Fig. 5F ). The tissues included in this work were mostly stage IIA and IIB. None of the IIA cases presented colocalization for STn with MUC1 or MUC5AC.
Determination of MUC5AC-SLe x glycoform in pancreatic cancer tissues by immunoprecipitation followed by Western blot.
The expression pattern of SLe x on MUC5AC, which showed the most promising results by PLA in this work, was further examined by a different approach. Western blot analyses of twenty micrograms of protein lysates from pancreatic adenocarcinoma and control pancreatic tissues were performed in duplicate in the same gel using Lum5.1 (anti-MUC5AC) and KM93 (anti-SLe x ) antibodies. MUC5AC
and SLe x were absent in normal pancreas (4/4), while 75% of the PDAC tissues (6 out of 8) presented a high molecular weight reactive band corresponding to MUC5AC (Fig. 6A) . All tissues that were positive for MUC5AC showed also positive staining for SLe x at the same molecular weight.
Remarkably, similar expression levels and band pattern for MUC5AC and SLe x were observed in each positive sample. The presence of vinculin, a constitutively expressed protein, of MUC1 and STn were also analysed by Western Blot on 20 micrograms of the protein lysates (Fig. S2 ). Vinculin expression was found similar among the samples. MUC1 was expressed in the normal pancreas and in most of the pancreatic cancer tissues and STn was not found in the control tissue and was expressed in some of the tumour tissues at different levels, which was in accordance with the IHC results. These results show that the differences found in mucins and carbohydrate antigen expression were intrinsic of each PDAC sample and not due to differences in the amount of total protein. Hence, suggesting that MUC5AC could be a major carrier of SLe x in PDAC tissues.
In order to validate that MUC5AC was bearing the SLe x epitope, a MUC5AC immunoprecipitation protocol from PDAC tissues was set up. Gel-forming mucins have an oligomeric structure stabilized by disulphide bonds and can be depolymerized by treatment with a reducing agent. Therefore, considering the complex nature of MUC5AC, reduction and alkylation of the lysed samples were performed to facilitate the immunocapture of MUC5AC. Although CLH2 and Lum5.1 anti- MUC5AC   709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754  755  756  757  758  759  760  761  762  763  764  765  766  767 antibodies were both assessed for immunoprecipitation, only the latter worked properly with our immunoprecipitation protocol (described in section 2.6). After sample immunoprecipitation of selected PDAC tissues, which expressed individually both MUC5AC and SLe x , a high molecular weight band above 250 kDa corresponding to MUC5AC was detected. Western blotting of the immunoprecipitated mucin probed with anti-SLe x antibody confirmed the presence of this epitope on MU5CAC (Fig. 6B) .
Overall, MUC5AC and SLe x colocalization was observed using both PLA and immunoprecipitation followed by western blotting.
Discussion
In this work we assessed the expression of MUC1 and MUC5AC as well as the cancer associated glycans SLe x and STn in pancreatic cancer tissues. Our results show the expression of SLe x in MUC5AC in most of the pancreatic cancer tissues as a promissing new biomarker of disease.
Secreted mucins, such as MUC5AC, protect epithelial cells from different harsh microenvironments forming a protective layer that allows the selective passage of molecules. Transmembrane mucins, like MUC1, apart from being sensors of the external environment, are engaged in signal transduction. The cytoplasmic tail of MUC1 is involved in several signalling pathways including those concerning Ras, β-catenin, p120 catenin, p53 and estrogen receptor α [51] . In tumour state, cancer cells express normal and new mucin core proteins with aberrant glycan structures that arise during disease progression to acquire new capabilities [8, 22, 40] . Studies with interference RNA specifically targeting MUC1 and MUC5AC showed a reduction of PDAC cells to adhere and invade [52, 53] , demonstrating the role of these mucins in PDAC progression and metastasis.
Mucins are considered a potential tool for the diagnosis and therapy of a wide range of cancers. More than 200 clinical studies have been conducted over the last three decades to evaluate mucins as therapeutic constituents or prognostic indicators [11, [54] [55] [56] .
PDAC is characterized by a lack of blood supply to tumours, whose surfaces are often coated with layers of dense, fibrous capsules, making the delivery of chemotherapy drugs difficult [7] . Target therapy using anti-MUC1 antibodies conjugated to radioactive elements and/or cytotoxic drugs that have shown to increase efficacy than radioimmunotherapy alone in prostate and ovarian cancers could 768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826 be potentially useful in PDAC [6, 11] . Moreover, several studies show that MUC1 [57] and STn epitope [58] can be successful in activating the immune system when injected as vaccines in MUC1 transgenic mice.
There are several antibodies against MUC1 displaying different staining patterns and percentages of positivity in normal pancreas and PDAC tissues [59, 60] . To our knowledge, this is the first time that the monoclonal antibody VU4H5 against MUC1 was used in the IHC analysis of pancreatic tissues.
Considering that the specificity described for VU4H5 is against the non-glycosylated APDTRPAP epitope within the tandem repeat sequence of MUC1 [60] [61] [62] , the low expression found in some tissues in this study could be explained by a possible glycosylation present on the MUC1 in PDAC. To address this issue, we have also used antibody M8 for the evaluation of MUC1 expression in the low MUC1 expressing cases, and higher positivity was observed. These results are in agreement with results from Hinoda and collaborators that found an increase in MUC1 detection in cancer tissues using an antibody directed against the core protein after deglycosylation [63] .
On the other hand, MUC5AC is being considered an interesting target for PDAC detection due to its neo-expression in pancreas during malignant transformation [6, 64] . Herein we showed the neoexpression of MUC5AC in PDAC in agreement with other authors [27] [28] [29] 40] .
Regarding the expression of tumour-associated carbohydrate antigens SLe x and STn, the detection in PDAC tissues and not in normal pancreas is in agreement with the reported literature [33] [34] [35] . The cancer associated expression of SLe x in pancreatic adenocarcinoma can be attributed to changes in glycosyltransferase expression [65] . An increase in α2,3-siayltransferases such as ST3GAL4 and in α1,3-fucosyltransferases such as FUT3 and FUT6 have been described in pancreatic adenocarcinoma tissues [66] . In addition, changes in nucleotide donor transporters and hypoxia have been reported to regulate SLe expression in colon cancer [67] [68] [69] . Since PDAC tumours are usually hypoxic due to poor vascularization [70] it is possible to postulate that the highly hypoxic environment of PDAC could be one of the factors inducing an increase in the glycosyltranferase expression and leading to an augment of SLe x expression.
In this work we have addressed whether SLe x and/or STn could be carried on MUC1 and MUC5AC mucins in PDAC. The presence of the sialylated epitopes SLe x and STn on MUC1 and MUC5AC has   827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870  871  872  873  874  875  876  877  878  879  880  881  882  883  884  885 been previously described by other authors in gastric, colon, lung, breast and ovarian cancer tissues [17, 39, [42] [43] [44] [45] as well as in pancreatic cancer cell line [71] , using PLA and other antibody-based approaches. Since an increase of truncated structures is a key feature of tumour cells [72] , we expected an increase in STn expression on MUC1 and MUC5AC. Although the expression of MUC1 bearing Tn/STn, detected by a specific anti-MUC1-Tn/STn antibody, in PDAC tissues has been reported by Remmers and collaborators [40] , our results do not show the same tendency. This could be due to the use of different antibodies, different methodology and different cohort. We have used a specific anti- Most of the currently used cancer biomarkers assays take advantage of changes in the biodistribution of tumour cell derived products [12, 20, 32] , such as the diagnostic serum tests that are based on changes in the level of the circulating mucins, MUC16 (CA125) [73, 74] and MUC1 (CA15-3) [75] , or changes in the mucin specific terminal glycan structures sialyl-Lewis a (CA19-9) [76, 77] or STn (CA72-4) [78, 79] . To date, there is no specific tumour marker to diagnose PDAC. The only marker approved by FDA to manage PDAC is CA19-9 that detects sialyl-Lewis a, an epitope found mainly on mucins [80] . Some mucin-based markers lack specificity due to their detection also in benign conditions. Glycan-based markers, on the other hand, present low tissue specificity since aberrant Oglycans can be found in many carcinoma tissues. Therefore, our strategy was the detection of a specific glycoform on a specific mucin that could circumvent these weaknesses and generate a biomarker with potential application for specific PDAC detection.
A good biomarker should be a molecule that can be found in blood or other fluids. However, due to the pathophysiology and micro-architecture of PDAC, which is poorly perfused and vascularized, secreted proteins that could be candidates for biomarkers have rarely been detected in circulation [81] . 886  887  888  889  890  891  892  893  894  895  896  897  898  899  900  901  902  903  904  905  906  907  908  909  910  911  912  913  914  915  916  917  918  919  920  921  922  923  924  925  926  927  928  929  930  931  932  933  934  935  936  937  938  939  940  941  942  943  944 On the other hand, PDAC tissue contains higher concentration of PDAC-specific markers and is the most direct source for the finding of cancer biomarkers [82, 83] . Thus, our strategy has been to analyse pancreatic tissues to identify candidates for their future validation in fluids, such as serum of PDAC patients. In the present study, the colocalization of MUC1 and MUC5AC with the tumour epitope SLe x presented a high specificity due to SLe x absence in non-malignant control tissue and has potential to be considered a PDAC biomarker. In this regard, further analyses of the glycan epitope SLe x on MUC1 and MUC5AC in serum from PDAC patients are warranted, particularly the MUC5AC-SLe x glycoform that showed 84% of expression in the MUC5AC expressing PDAC tumours, including poorly, moderately and highly differentiated tissues.
Conclusions
In this study, we have evaluated the anti-MUC1 VU4H5 antibody in pancreatic tissues and we have also studied the colocalization of the tumour associated antigens SLe x and STn within the mucins 945  946  947  948  949  950  951  952  953  954  955  956  957  958  959  960  961  962  963  964  965  966  967  968  969  970  971  972  973  974  975  976  977  978  979  980  981  982  983  984  985  986  987  988  989  990  991  992  993  994  995  996  997  998  999  1000  1001  1002  1003 The stage II* refers to a patient that the N (regional lymph nodes) cannot be addressed. 
